Contact
      Please use this form to send email to PR contact of this press release:
      
      HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
    
      TO: